



February 10, 2026

### **Notice Regarding Offer of Refunds to 340B Covered Entities**

GlaxoSmithKline (“GSK”) recently recalculated 340B Ceiling Prices for the NDCs referenced below for the time period of January 1, 2024 through March 31, 2024 (1Q2024). As a result of the recalculation, GSK has determined that (pursuant to 42 U.S.C. § 256b(d)(1)(B)(ii) and 42 C.F.R. § 10.11(b)(4)), a refund is or may be due to any 340B Covered Entity which purchased any of the below NDCs during the aforementioned time period.

The table below identifies the NDCs that are subject to a refund. The recalculated Ceiling Prices are the result of revised pricing data that were submitted to the Centers for Medicare & Medicaid Services.

Time Period	Product	NDc-11
01/01/2024 – 03/31/2024	ANORO ELLIPTA 62.5/25 MCG INH PWDR 1X30 DS	00173-0869-10
01/01/2024 – 03/31/2024	ANORO ELLIPTA 62.5/25 MCG INH PWDR 1X7 DS INST	00173-0869-06
01/01/2024 – 03/31/2024	ARNUITY (FF) ELLIPTA INH PWDR 50MCG 1X30 DOSE TRD	00173-0888-10
01/01/2024 – 03/31/2024	ARNUITY ELLIPTA 100MCG DRY PWD INH 1X 14D INST	00173-0874-14
01/01/2024 – 03/31/2024	ARNUITY ELLIPTA 100MCG DRY PWD INH 1X 30D TRD	00173-0874-10
01/01/2024 – 03/31/2024	ARNUITY ELLIPTA 200MCG DRY PWD INH 1X 14D INST	00173-0876-14
01/01/2024 – 03/31/2024	ARNUITY ELLIPTA 200MCG DRY PWD INH 1X 30D TRD	00173-0876-10
01/01/2024 – 03/31/2024	BREO ELLIPTA 100/25 MCG INH PWDR 14 DOSE NDPI INST PACK X 1	00173-0859-14
01/01/2024 – 03/31/2024	BREO ELLIPTA 100/25 MCG INH PWDR 30 DS NDPI TRD PACK X 1	00173-0859-10
01/01/2024 – 03/31/2024	BREO ELLIPTA 200/25 MCG INH PWDR 1X 14D INST	00173-0882-14
01/01/2024 – 03/31/2024	BREO ELLIPTA 200/25 MCG INH PWDR 1X 30D	00173-0882-10
01/01/2024 – 03/31/2024	INCRUSE ELLIPTA INH PWDR 62.5MCG 1X30 DOSE TRD	00173-0873-10
01/01/2024 – 03/31/2024	INCRUSE ELLIPTA INH PWDR 62.5MCG 1X7 DOSE INST	00173-0873-06
01/01/2024 – 03/31/2024	NUCALA SOLUTION INJECT SS 40MG/0.4ML 1X1	00173-0904-42
01/01/2024 – 03/31/2024	TRELEGY ELLIPTA 200/62.5/25MCG 1X14D INST PACK	00173-0893-14
01/01/2024 – 03/31/2024	TRELEGY ELLIPTA 200/62.5/25MCG 1X30D TRADE PACK	00173-0893-10
01/01/2024 – 03/31/2024	TRELEGY ELLIPTA INH PWDR 100/62.5/25MCG 1X14 DOSE INST	00173-0887-14
01/01/2024 – 03/31/2024	TRELEGY ELLIPTA INH PWDR 100/62.5/25MCG 1X30 DOSE TRD	00173-0887-10
01/01/2024 – 03/31/2024	VENTOLIN HFA 90MCG INH AER 60 ACTN	00173-0682-24
01/01/2024 – 03/31/2024	VENTOLIN HFA DC INH.AER. 18G 200INHL 1S	00173-0682-20

GSK intends to refund any amount equal to or in excess of \$100 (aggregate for all applicable NDCs) for the periods listed directly to the 340B Covered Entity of record. Separate correspondence including a check and details of the payment will be sent to the qualifying 340B Covered Entity.

For 340B Covered Entities who may be owed less than \$100 in aggregate or who have questions about the above-referenced recalculation for this period, GSK invites interested parties to contact it via email at [GSK.340BRefunds@gsk.com](mailto:GSK.340BRefunds@gsk.com), with a reference to the NDC and time period.

GSK has asked the Health Resources and Services Administration (HRSA) to post this Notice on the HRSA's public website to ensure transparency to all 340B Covered Entities regarding the Ceiling Price recalculations for all NDC's identified above and to offer a refund to any of the 340B Covered Entities that may have purchased the above NDCs during the relevant time periods. Please direct any questions and/or requests for additional information to GSK at the following email address: [GSK.340BRefunds@gsk.com](mailto:GSK.340BRefunds@gsk.com).